Literature DB >> 11902735

High-grade osteosarcoma of the extremity: differences between localized and metastatic tumors at presentation.

Gaetano Bacci1, Stefano Ferrari, Alessandra Longhi, Cristiana Forni, Marcello Zavatta, Michela Versari, Keith Smith.   

Abstract

BACKGROUND: In osteosarcoma, as in other tumors, the presence of metastases at presentation is generally considered a consequence of late diagnosis. To verify this, the authors investigated whether there was a relationship between the stage of the disease at presentation and several clinical and pathologic characteristics, including the interval between the onset of first symptoms or signs and the final diagnosis. PATIENTS AND METHODS: One thousand seventy-one patients with high-grade osteosarcoma of the extremity were observed between 1980 and 1999. Of these, 891 had a localized tumor and 180 had metastases at the time of diagnosis.
RESULTS: Compared with patients with localized disease, patients with detectable metastases at the time of diagnosis had higher serum levels of alkaline phosphatase, larger primary lesions, and tumors often located in the femur and humerus. In terms of time to diagnosis, the interval between the onset of first symptoms and the final diagnosis was significantly shorter in patients with metastases than in patients with localized tumor. This surprising finding probably reflects a more rapid growth of the tumor.
CONCLUSIONS: These results suggest a different biologic phenotype and aggressiveness of the tumor in a subgroup of patients and that the stage of the disease at presentation depends more on the properties of these tumors than on late diagnosis.

Entities:  

Mesh:

Year:  2002        PMID: 11902735     DOI: 10.1097/00043426-200201000-00008

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  17 in total

1.  XB130 expression in human osteosarcoma: a clinical and experimental study.

Authors:  Xiaohui Wang; Ruiguo Wang; Zhaolong Liu; Fengyun Hao; Hai Huang; Wenchen Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison.

Authors:  Tracy A Marko; Brandon J Diessner; Logan G Spector
Journal:  Pediatr Blood Cancer       Date:  2016-02-29       Impact factor: 3.167

3.  C-kit expression in human osteosarcoma and in vitro assays.

Authors:  Luciana N O Miiji; Antonio S Petrilli; Sebastian Di Cesare; Alexandre N Odashiro; Miguel N Burnier; Silvia R de Toledo; Reynaldo Jesus Garcia; Maria Teresa S Alves
Journal:  Int J Clin Exp Pathol       Date:  2011-11-03

4.  Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis.

Authors:  Antonieta Medina-Lara; Bogdan Grigore; Ruth Lewis; Jaime Peters; Sarah Price; Paolo Landa; Sophie Robinson; Richard Neal; William Hamilton; Anne E Spencer
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.014

5.  Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma.

Authors:  Kjetil Berner; Tom Børge Johannesen; Aasmund Berner; Hans Kristian Haugland; Bodil Bjerkehagen; Per J Bøhler; Øyvind S Bruland
Journal:  Acta Oncol       Date:  2014-06-24       Impact factor: 4.089

Review 6.  Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review.

Authors:  R D Neal; P Tharmanathan; B France; N U Din; S Cotton; J Fallon-Ferguson; W Hamilton; A Hendry; M Hendry; R Lewis; U Macleod; E D Mitchell; M Pickett; T Rai; K Shaw; N Stuart; M L Tørring; C Wilkinson; B Williams; N Williams; J Emery
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

7.  Factors associated with delayed cancer diagnosis in egyptian children.

Authors:  Er Abdelkhalek; Lm Sherief; Nm Kamal; Rm Soliman
Journal:  Clin Med Insights Pediatr       Date:  2014-09-04

8.  Prognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient.

Authors:  Kjetil Berner; Kirsten Sundby Hall; Odd R Monge; Harald Weedon-Fekjær; Olga Zaikova; Øyvind S Bruland
Journal:  Sarcoma       Date:  2015-02-17

9.  Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy.

Authors:  Rosalvo Zósimo Bispo Júnior; Olavo Pires de Camargo
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

10.  IS THERE ANY DIFFERENCE IN THE PROGNOSIS FOR PATIENTS WITH PRIMARY OSTEOSARCOMA WITH A POOR RESPONSE TO NEOADJUVANT CHEMOTHERAPY BETWEEN HUVOS GRADES I AND II?

Authors:  Rosalvo Zósimo Bispo Júnior; Olavo Pires de Camargo
Journal:  Rev Bras Ortop       Date:  2015-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.